NO20071352L - Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX - Google Patents

Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX

Info

Publication number
NO20071352L
NO20071352L NO20071352A NO20071352A NO20071352L NO 20071352 L NO20071352 L NO 20071352L NO 20071352 A NO20071352 A NO 20071352A NO 20071352 A NO20071352 A NO 20071352A NO 20071352 L NO20071352 L NO 20071352L
Authority
NO
Norway
Prior art keywords
dosage forms
dose
dosage
cave
dosage form
Prior art date
Application number
NO20071352A
Other languages
English (en)
Norwegian (no)
Inventor
Curtis Wright
Robert Colucci
Ahmed El-Tahtawy
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20071352L publication Critical patent/NO20071352L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20071352A 2004-09-01 2007-03-13 Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX NO20071352L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60635404P 2004-09-01 2004-09-01
PCT/US2005/030892 WO2006028830A2 (en) 2004-09-01 2005-08-30 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax

Publications (1)

Publication Number Publication Date
NO20071352L true NO20071352L (no) 2007-05-30

Family

ID=35759199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071352A NO20071352L (no) 2004-09-01 2007-03-13 Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX

Country Status (15)

Country Link
US (2) US9326959B2 (ko)
EP (1) EP1786404A2 (ko)
JP (1) JP4997109B2 (ko)
KR (2) KR20070048272A (ko)
CN (1) CN101010072A (ko)
AU (1) AU2005282784B2 (ko)
BR (1) BRPI0515600A (ko)
CA (1) CA2578540A1 (ko)
EA (1) EA010627B1 (ko)
IL (1) IL181600A0 (ko)
MX (1) MX2007002135A (ko)
NO (1) NO20071352L (ko)
UA (1) UA85750C2 (ko)
WO (1) WO2006028830A2 (ko)
ZA (1) ZA200700620B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
CA2665841C (en) 2006-10-09 2016-04-05 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP5607550B2 (ja) * 2008-03-11 2014-10-15 ディポメド，インコーポレイティド 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US8753677B2 (en) 2008-09-16 2014-06-17 The Invention Science Fund I, Llc Ex vivo modifiable multiple medicament final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
US20140161879A1 (en) * 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910002669B1 (ko) 1986-12-25 1991-05-03 데이산세이야꾸 가부시끼가이샤 서방성 과립 및 그를 함유하는 지속성 복합과립
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
KR100341829B1 (ko) * 1996-03-08 2002-08-22 니코메드 덴마크 에이/에스 방출특성이변형된다-유니트투여량조성물
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
KR101476574B1 (ko) * 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU1930301A (en) 1999-12-08 2001-06-18 Pharmacia Corporation Valdecoxib compositions
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6874926B2 (en) * 2001-11-26 2005-04-05 Nokia Corporation Illumination system for an electronic device
DK200200669A (da) * 2002-05-02 2003-11-03 Schur Packaging Systems As Fremgangsmåde og apparat til fyldning af indhold i folieposer samt emballageemne til anvendelse ved fremgangsmåden og i apparatet

Also Published As

Publication number Publication date
JP4997109B2 (ja) 2012-08-08
EA010627B1 (ru) 2008-10-30
KR20070048272A (ko) 2007-05-08
US20140187572A1 (en) 2014-07-03
CN101010072A (zh) 2007-08-01
BRPI0515600A (pt) 2008-07-29
US20080132532A1 (en) 2008-06-05
MX2007002135A (es) 2007-04-02
UA85750C2 (uk) 2009-02-25
US9034377B2 (en) 2015-05-19
ZA200700620B (en) 2008-04-30
AU2005282784A1 (en) 2006-03-16
CA2578540A1 (en) 2006-03-16
KR20080046751A (ko) 2008-05-27
EP1786404A2 (en) 2007-05-23
IL181600A0 (en) 2007-07-04
AU2005282784B2 (en) 2008-06-19
EA200700500A1 (ru) 2007-08-31
US9326959B2 (en) 2016-05-03
JP2008511657A (ja) 2008-04-17
WO2006028830A2 (en) 2006-03-16
WO2006028830A3 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20071352L (no) Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX
Jing et al. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review
Fielding-Singh et al. Beyond low tidal volume ventilation: treatment adjuncts for severe respiratory failure in acute respiratory distress syndrome
CY1122698T1 (el) Ελιγλουστατη (genz 112638) ως αναστολεας της συνθετασης γλυκοζυλοκεραμιδιου για χρηση σε μια μεθοδο θεραπευτικης αγωγης της νοσου fabry ή gaucher, με τη μεθοδο να περιλαμβανει την προσαρμογη της ατομικης θεραπευτικης δοσης στον ρ-450 μεταβολισμο του ασθενους
MX2020006650A (es) Esketamina para el tratamiento de la depresión.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2018011349A (es) Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica.
UY28945A1 (es) Derivados de pirrolopiridina
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
NO20064964L (no) Behandling av svekket respiratorisk funksjon
DE602005023203D1 (de) Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung
JP2017528483A5 (ko)
NO20054711L (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
CL2021003280A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
MX2009011900A (es) Curacion de herida diabetica.
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
Pešić et al. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
Bernstein et al. Efficacy of omalizumab in patients with chronic idiopathic/spontaneous urticaria with different background therapy: post hoc analysis of Asteria I, Asteria II, and Glacial studies
HUP0303468A2 (hu) Egy vagy több shogaol alkalmazása afrodiziákumként
Alva Importance of achieving rapid treatment response in major depressive disorder
Saini et al. Whole blood histamine concentration response to omalizumab in patients with chronic idiopathic/spontaneous urticaria: post hoc analysis of ASTERIA I, ASTERIA II and GLACIAL studies

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EURO-CELTIQUE SA, LU

FC2A Withdrawal, rejection or dismissal of laid open patent application